TITLE

GKS: A Pipeline to Brag About?

AUTHOR(S)
Houlton, Sarah
PUB. DATE
January 2004
SOURCE
Pharmaceutical Executive;Jan2004, Vol. 24 Issue 1, p22
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports the claim by Jean-Pierre Garnier, chief executive officer of GlaxoSmithKline PLC (GSK), that of the 147 products GSK has in clinical trials, at least 20 have blockbuster potential. Drop in the company's price share; Potential of the company's therapeutic areas; Company's reorganization.
ACCESSION #
12016480

 

Related Articles

  • Fat-cat salaries are the best way to get the cream. Pitcher, George // Marketing Week;5/29/2003, Vol. 26 Issue 22, p27 

    Focuses on the salary of executives in Great Britain. Increase in the remuneration received by executives in the oil industry as a result of the Iraq conflict; Dissention of the public, especially the press, against the increase in pay received by executives; Issue concerning the proposed pay...

  • Good Science And The Marketplace For Drugs: A Conversation With Jean-Pierre Garnier. Iglehart, John K. // Health Affairs;Jul/Aug2003, Vol. 22 Issue 4, p119 

    Interviews Jean-Pierre Garnier, chief executive officer of GlaxoSmithKline. Expansion of the scope of Medicare's prescription drug benefits; GlaxoSmithKline's drug research and development activities; Challenges posed by the generic market; Future of drug development.

  • WISDOM FROM BIG PHARMA'S DR. GLOOM. Lustgarten, Abrahm // Fortune International (Europe);3/21/2005, Vol. 151 Issue 5, p20 

    Presents an interview with GlaxoSmithKline CEO Jean-Pierre Garnier. Thoughts on challenges facing the pharmaceutical industry, including the development of meaningful drugs; Signing with Human Genome Sciences to use gene sequencing technology to help develope new drugs; Comments on the...

  • GSK Names New Chairman.  // Pharmaceutical Technology;Mar2006, Vol. 30 Issue 3, p174 

    The article announces the appointment of Moncef Slaoui as chairman of research and development at GlaxoSmithKline effective June 1, 2006. Slaoui will report to Chief Executive Officer Jean-Pierre Garnier. Slaoui succeeds Tadataka Yamada who will retire from the company to become executive...

  • WISDOM FROM BIG PHARMA'S DR. GLOOM. Lustgarten, Abrahm // Fortune;3/21/2005, Vol. 151 Issue 6, p38 

    Presents an interview with GlaxoSmithKline CEO Jean-Pierre Garnier. Thoughts on challenges facing the pharmaceutical industry, including the development of meaningful drugs; Signing with Human Genome Sciences to use gene sequencing technology to help develope new drugs; Comments on the...

  • GSK Revisits Exec Pay. Houlton, Sarah // Pharmaceutical Executive;Feb2004, Vol. 24 Issue 2, p28 

    Reports on the plan created by GlaxoSmithKline PLC for compensating senior executives to replace a plan rejected by stockholders in Great Britain. Problem of investors with the original proposal; Changes made to the contracts of other executive directors; Salary and bonus package received by...

  • Fat cat cream goes sour.  // European Chemical News;5/26/2003, Vol. 78 Issue 2054, p5 

    Comments on the decision of GlaxoSmithKline (GSK) shareholders to vote down the proposed remuneration package for chief executive officer Jean-Pierre Garnier. Amount of the proposed package; Argument of shareholders against the proposal; Implication of the GSK vote.

  • WALL STREET CHOICE: UPSIDES TO GARNIER'S DEPARTURE KEEPS GSK NEUTRAL BUY.  // Medical Marketing & Media;Nov2007, Vol. 42 Issue 11, p34 

    The article reports on the performance rate of GlaxoSmithKline (GSK) in research and development. The value embedded in the company has been rated as neutral due to some uncertainties associated with the exit of chief executive officer (CEO) Jean-Pierre Garnier in the company. The low commercial...

  • Gamier Takes the Reigns. Houlton, Sarah // Pharmaceutical Executive;Oct2008, Vol. 28 Issue 10, p22 

    The article reports that Jean-Pierre Garnier, who has resigned from GlaxoSmithKline, is going to France to take his role as general manager of Pierre Fabre Pharmaceuticals Inc. Accordingly, Pierre Fabre Pharmaceuticals Inc., made a turnover of $45 billion in 2007, with its biggest selling...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics